Prof. Dr. ir. Jonathan A. Lal
Prof. Dr. ir. Jonathan A. Lal
Professor


Department
Department of Molecular & Cellular Engineering
Qualification
B.Tech.; M.Sc.; PDEng.; Ph.D
Area of Specialization
Biotechnology, Public Health Genomics, Bioproduct Design
Phone No
+91-532-2684402
E-mail
jonathanalal@shiats.edu.in, jonathanalal@shuats.edu.in

Educational Details
DegreeUniversity/BoardYear
Ph.DMaastricht University (UM), Netherlands2013
PDEngDelft University of Technology, Netherlands2009
M.ScDelft University of Technology, Netherlands2007
B.TechAAIDU, Allahabad2005


Professional Summary

Dr. ir. Lal is working as Director (Innovation, Projects & Consultancy), Dean (Jacob Institute of Biotechnology & Bioengineering) and Professor (Biotechnology), all at Sam Higginbottom University of Agriculture, Technology & Sciences, India. 

Previously, he worked in the Netherlands as the CEO - ptTheragnostic BV, Director - Health Innovation Ventures BV & prior to that CSO - ptTheragnostic BV. He was also a researcher in the department of Radiotherapy, Maastricht University & CSO - Maastro Clinic, both in the Netherlands. 

Prior to this, he worked as a researcher at the Institute for Public Health Genomics at Maastricht University, the Netherlands. During this time he was also the project manager of the ERA-NET ERAfrica project 'InnXchange'.

Before that, during his time at Maastricht University, he had also worked as the project manager of the EU DG SANCO 'Public Health Genomics European Network' and had also worked as a B-Team member for the EU pilot flagship project IT Future of Medicine. In addition, he had briefly worked as a research advisor for the European Alliance for Personalised Medicine (EUAPM). 

Previous to this, he worked as a Bioproduct Designer at Delft University of Technology, the Netherlands. 

He has experience with entrepreneurship, valorization, management, financial administration, negotiations, contracts, spin-offs, acquisitions, business development, health policy, best practice guidelines, personalized medicine, public health genomics, biotech, proteomics, molecular biology, grant writing, teaching and research.

He has a Cum Laude PhD in Public Health Genomics (Maastricht University), a Professional Doctorate in Engineering in Bioproduct Design (Delft University of Technology), did his Master’s degree in Life Science & Technology with a specialization in cell diagnostics (Delft University of Technology) and did his Bachelor’s degree (B.Tech, gold medal) in Biotechnology with a specialization in genetic engineering (Allahabad Agricultural Institute-Deemed University, India).


Expertise

Applied translational skills:

Public Health Genomics, Biotechnology, Techno-economic Evaluation, Entrepreneurship, Grant Writing, License Negotiations, Contract Negotiations, Shares Purchase Agreement, Material Transfer Agreements, Hiring, Market Research, SWOT Analysis, Valorization, Patent Analysis, Project Management, Product Design & Innovation, Business Development, Corporate Finance, Tax Compliance, Translational Research, Technology Transfer, Health Policy, Healthcare Systems, Administration, Policy Advise on European Level.

Wet-lab:

Affymetrix mtDNA chips, Nano-LC-MALDI/MS (Liquid Chromatography-Matrix Assisted Laser Desorption/Ionization Mass Spectrometry), Yeast Two-Hybrid System, Flourescence Microscopy, Electrospray, PCR (Polymerase Chain Reaction), Molecular Cloning, Plasmid Vector Construction, Nano-Spectrophotometry, SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis), Western Blotting, β-Gal Assay, Agarose Gel Electrophoresis, Transformation, Plasmid, Genomic & Crude DNA Isolation Techniques, Chromosome counting, rDNA Technology, Cell Cultures, Basic Bioinformatics and other basic molecular biology techniques. 


Projects

LIST OF FORMER PROJECTS PREVIOUSLY INVOLVED IN:

RAIL: non-invasive stratification of tumour heterogeneity for personalised cancer therapy
This is a € 2.4 million EU Horizon 2020 grant (2015-2019). The breakthrough technology, called “Radiomics”, which was recently published in Nature Communications, enables patient stratification through the use of imaging biomarkers acquired from routine CT & PET imaging. In Radiomics for lung cancer (RAIL) we validate and qualify a multi-site level I imaging biomarker together with a ready-to-use application to deliver more accurate prognostic information, personalise treatment for non-small cell lung cancer patients, reduce healthcare costs by EUR 500+ million and enable efficient clinical trial design

Mitochondrial genetics for the prediction of radiotherapy-induced lung toxicity risk: a prospective multicenter and mechanistic study
This is a € 572,500 Euros Dutch grant from the Dutch Cancer Society (KWF) to do research on “mitochondrial genetics for the prediction of radiotherapy-induced lung toxicity risk: a prospective multicenter and mechanistic study”. This study involves a large cohort of patients for establishing mitochondrial biomarkers to assess adverse effects induced in the irradiation.

Efficient integration of genome-based technologies into the health care system
Awarded as the APOGEE-Net/CanGeneTest Network pilot project from the APOGEE- Net/CanGeneTest Research and Knowledge Network on Genetic Services and Policy, Canada with a duration from 2011-2015. APOGEE-Net/CanGeneTest was formed in 2009 with a 5 year funding from CIHRs Institute of Genetics and Institute of Health Services and Policy Research. The general objective of the research and knowledge network is to streamline the technology transfer of clinically useful and cost effective genetic innovations towards the health care systems and support the development of evidence informed health policy.

Platform for sharing best practices for management of rare diseases (RARE-Bestpractices)
This is an EU framework program 7 grant planned as a 4-years project (2013-2016) that will develop a sustainable global networking platform, supporting the collection of standardized and validated data and the exchange of knowledge and reliable information among a multiplicity of countries. Its main goal is to improve clinical management of rare disease patients and narrow the existing gap in quality of health care among EU Member States as well as in other countries, by collecting, evaluating and disseminating best practices and sharing knowledge globally also considering the application of patients’ rights in cross-border healthcare EU Directive 2011/24.

An integrated European Platform for Pancreas Cancer Research: From Basic Science to Clinical and Public Health Interventions for a rare disease
This is a COST (European Cooperation in Science and Technology) EU framework program 7 grant (2013-2016) that proposes the creation of a unique European platform to facilitate the collaboration of a broad range of European and international PDAC (rare and dreadful diseases like pancreas cancer) multidisciplinary research groups to integrate knowledge and experience in a multidisciplinary way “from cell to society”; promote the application of uniform study tools and protocols; foster their optimal use by early-stage researchers; enhance the mobility and training of researchers; and permeate the society with the results originated by the Action. This Action will develop novel interdisciplinary tools that will improve our understanding of PDAC and its control by answering questions related to the aetiology, early detection and evidence-based and personalized treatment to enhance primary, secondary, an tertiary prevention, respectively, as well as on health management.

Increasing innovation potential by European-African Cooperation (InnXchange)
This is an EU framework program 7 planned as a 2 years project. The project aims to develop guidelines on innovation creation and innovation management, more specifically on how to identify research problems with real-world relevance, identify innovative solutions to those problems, evaluate the potential of ideas in terms of technical innovation, evaluate the potential of the ideas in terms of market demand and commercialization, consider the relevance of IPR and convert an innovation into a commercial product. This project has a duration of 2 years (2014-2016) and includes partners from South Africa, Kenya, Germany and the Netherlands.

PerMed
Personalized medicine is on of the most innovative areas in the future of health research. However, today the full potential cannot be developed due to fragmented activities, insufficient communication and lack of generic solutions in the different areas. Therefore, the implementation of personalized medicine is a major challenge for Europe. The coordination and support action (CSA) PerMed (Personalized Medicine) was initiated to step up coordination efforts between European key stakeholders to allow synergies and avoid duplication or competition, to ensure maximum transparency and openness. PerMed aims to complement existing activities by identifying and promoting promising research topics, develop strategic research and innovation agendas in Europe and beyond and to bring forward the implementation of personalized medicine for the benefit of society.

Information and Communication Technology Future of Medicine (ITFoM)
This was an EU framework program (FP7) Flagship Pilot Project (duration 2011-2012). ITFoM wished to harness the vast potential of ICT to revolutionize human health care. The idea is to exploit the unprecedented amounts of detailed biological data for individual people, and turn this information into actual knowledge that helps us in taking medical and lifestyle decisions. By integrating the available biological data the aim is to construct computational models of the biological processes that occur in every human. Since everybody is different, the models will be tailored to each individual to reflect their own unique anatomical, physiological and genetic makeup. Our role is to ensure the smooth transition from the lab to healthcare systems by the time the technology is ready.

Ex-post evaluation of the health theme in framework program 7 – case studies
This is an EU RTD Tender. The study is expected to analyze the appropriateness and impact of the NMP-FP7 program, regarding the European societal and economic policies and needs. It shall analyze the objectives of the NMP-FP7 program, its implementation and execution, the outcome and impact of projects, and the efficiency of the program. It is supposed to develop recommendations for future European funding policy in the fields covered by the NMP program. Our focus here is on personalized medicine and medical technologies.

Public Health Genomics European Network (PHGEN II)
PHGEN II project was supported by a grant from the European Commission (2009-2012) with DG SANCO EU-Project No. 20081302. PHGEN II fulfils priority action 3.4.3.2 of WP 2008 by producing the first edition of “European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies”. It builds on the experiences of PHGEN I (Public Health Genomics European Network) which was a networking exercise to develop a common understanding of Public Health Genomics between all stakeholders in Europe and which identified the need for European coherent guidelines in that field. The consortium had over 22 partners.

Barriers and Access to Personalized Medicine in EU
This project developed several surveys for multi-stakeholders on personalized medicine to identify risks, barriers and access to personalized medicine in the EU with the overall objective to develop an EU personalized medicine index. The project was granted through the European Alliance for Personalised Medicine (EAPM).

Workshop on the Learning-Adapting-Leveling model
This workshop was developed and executed to help stakeholders understand the multi- faceted translational research pipeline, its bottlenecks, and potential solutions to resolve the bottlenecks. Stakeholders came from across the EU which included industry, EC, HTA professionals, patient groups, etc. The workshop was organized at the European Alliance for Personalised Medicine (EAPM).

PhD Thesis

Valorization in Public Health Genomics: A Conceptual Development from Technology Transfer to Healthcare Integration, Maastricht University, Netherlands

Individual Design Project

On “Feasibility Studies and Design of Nanotitre Fill Plate Technology” in the Analytical Biotechnology Group at the department of Biotechnology, Delft University of Technology (TU Delft), Netherlands. This project was based around the TU Delft patent “method of the dosed application of a liquid onto a substrate”. (September 2008 - August 2009)

Group Design Project

Design of Polyhydroxyalkanoates (PHA)-based intermediate products from waste streams for clients DSM BV and Paques BV www.dsm.nl www.paques.nl. This was based on a TU Delft (Netherlands) patent. (January 2008 - August 2008)

Business Evaluation

Detailed Techno-economic evaluation of PHA-based products for market entry and feasibility, TU Delft Netherlands (June 2008 - August 2008)

Turning Technology into Business

Research, analysis and evaluation of the TU Delft patent ‘system and method for integration of renewable energy and fuel cell for the production of electricity and hydrogen’ for possible business development and implementation, Netherlands. (September 2007 - January 2008)

Master Thesis

Master Thesis on “Agrobacterium-mediated transformation of eukaryotic cells: the use of the yeast Saccharomyces cerevisiae to study the role of chromosome remodeling in T-DNA integration” in the department of Molecular & Developmental Genetics at the Institute of Biology, Leiden University, the Netherlands. (January 2007 - August 2007)

Industrial Internship

Did literature study research on “Diabetes Type II and the Role of DNA Damage” for DNage BV, a biopharmaceutical company based in Leiden Netherlands. (September 2006 - December 2006)

Design Project

Designed a “Biosensor for detecting amount of growth factors required for dosage on site to increase facture healing” and did market research along with colleagues with regard to “Synthetic osteoinductive calcium phosphate bone filler material” for Progentix, a Life Science company based in Bilthoven Netherlands. (May 2006 - August 2006)

Bachelor Thesis

Thesis on “PCR amplification and cloning of gene encoding ribosomal inactivating protein from Chenopodium (Chenopodium album)” , AAIDU India. (January 2005 - June 2005)


Publications

2011

  • Lal JA, Schulte in den Baümen T, Morré SA, Brand A. Public Health and Valorization of Genome-based Technologies: A new model. Journal of Translational Medicine 2011, 9:207. 2012

  • Brand A., Lal JA. European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies – the 2012 Declaration of Rome. Drug Metabolism and Drug Interactions 2012, 27(3):177-182.

2012

  • Soltani J, Lal JA, van Heusden GPH, Hooykaas PJJ. Nuclear localization of Agrobacterium VirD2 in the yeast Saccharomyces cerevisiae. Novin Genetics 2012, 29(2):157-164.

2013

  • Lal JA, Malogajski J, Verweij SP, de Boer P, Ambrosino E, Brand A, Oudburg S, Morré SA. Chlamydia trachomatis infections and subfertility: opportunities to translate host pathogen genomic data into public health. Public Health Genomics 2013, 16:50-61.

  • Brand A, Lal J, Malats N, Gutierrez-Ibarluzea I. The Public Health Genomics European Network (PHGEN). The Newsletter of the British Society for Human Genetics 2013, 48, 53-55.

  • Lal JA. Addressing the backlog of genome-based technologies in healthcare. The Newsletter of the British Society for Human Genetics 2013, 48, 60-61. 

  • Lal JA, Sudbrak R, Lehrach H, Brand A. Functional Dynamics: From Biological Complexity to Translation and Impact in Healthcare Systems. Journal of Computer Science and Systems Biology 2013, 6:88-92.

  • Lal JA, Vaidya A, Gutiérrez-Ibarluzea I, Dauben HP, Angela Brand. The LAL Model: from theory to hypothesis of steps for implementation of basic genome-based evidences in personalized medicine. Personalized Medicine 2013, 10(7):683-701.

2014

  • Lal JA, Morré SA, Brand A. The overarching framework of translation and integration: a casefor the LAL model. Personalized Medicine 2014, 11(1):41-62.

  • Taruscio D, Morciano C, Laricchiuta P, Mincarone P, Palazzo F, Leo CG, Sabina S, Guarino R, Auld J, Sejersen T, Gavhed D, Ritchie K, Hilton-Boon M, Manson J, Kanavos PG, Nicod E, Tordrup D, Angelis A, Cam YL, Ensini M, Senecat J, Filippini G, Minozzi S, Giovane CD, Schünemann H, Meerpohl JJ, Prediger B, Schell L, Stefanov R, Iskrov G, Miteva-Katrandzhieva T, Serrano-Aguilar P, Perestelo-Perez L, Trujillo-Martín MM, Pérez-Ramos J, Rivero-Santana A, Brand A, Lal J, van Kranen H, Bushby K, Atalaia A, Ramet J, Siderius L, Posada M, Abaitua- Borda I, Alonso Ferreira V, HensPérez V. RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases. Rare Diseases and Orphan Drugs 2014, 1(1):5-9.

  • Sejersen T, Giovane CD, Filippini G, Leo CG, Meerpohl JJ, Mincarone P, Minozzi S, Sabina S, Schünemann H, Senecat J, Taruscio D, Morciano C, Laricchiuta P, Auld J, Gavhed D, Ritchie K, Boon MH, Manson J, Kanavos PG, Tordrup D, Nicod E, Guarino R, Ensini M, Cam YL, Prediger B, Schell L, Miteva-Katrandzhieva T, Stefanov R, Iskrov G, Serrano-Aguilar P, Perestelo-Perez L, Trujillo-Martín MM, Rivero A, Brand A, van Kranen H, Lal J, Morre S, Bushby K, Atalala A, Siderius L, Ramet J, Posada M. Methodology for production of best practice guidelines for rare diseases. Rare Diseases and Orphan Drugs 2014, 1(1):10-19.

  • Leyens L, Horgan H, Lal JA, Steinhausen K, Satyamoorthy K, Brand A. Working towards personalization in medicine: main obstacles to reaching this vision from today’s perspective. Personalized Medicine 2014, 11(7):641-649.

  • Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, Bubhoff, Ballensiefen W, Brand A. An Index of Barriers in Access to Personalised Medicine in Europe. Public Health Genomics 2014, 17:287-298.

2015

  • Boon HM, Harbour J, Ritchie K, Thompson L, Taruscio D, Morciano C, Laricchiuta P, Tonon S, Auld J, Sejersen T, Gavhed D, Kanvos PG, Mincarone P, Leo CG, Sabina S, Guarino R, Palazzo F, Ponzini G, Senecat J, Boudes M, LeCam Y, Filippini G, D’Amico R, Minozzi S, Giovane CD, Schunemann H, Meerpohl J, Iorio A, Schell L, Miteva-Katrandzhieva T, Stefanov R, Iskrov G, Serrano-Aguilar P, Perestelo-Perez L, Tryjillo-Martin M, Ramos JP, Rivero A, Brand A, Lal J, van Kranen H, Bushby K, Atalaia A, Siderius L, Ramet J, Posada M, Hens-Perez M, Abaitua I, Manzanares FJ, Alonso V, North K. Report of an international workshop to explore the utility of the AGREE II instrument for appraisal of rare disease guidelines. Rare Diseases and Orphan Drugs 2015, 2(1):11-15.

2016

  • Lambin P, Zindler J, Vanneste B, Van De Voorde L, Eekers D, Compter I, Panth K, Peerlings J, Larue R, Deist T, de Jong E, Even A, Reymen B, Lustberg T, van Soest J, Rekers N, Roelofs E, Carvalho S, Leijenaar R, van Gisbergen M, Zegers C, Jacobs M, Brouwers P, van Timmeren J, Jochems A, Lal JA, Yaromina A, Ramaekers B, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Dubois L, Dekker A, Boersma L, Hoebers F, Smits K, Berlanga A, Walsh S. Decision Support Systems for Personalized and Participative Radiation Oncology. Advanced Drug Delivery Reviews 2017, 109:131-153 (Accepted 6 January 2016, Available online 14 January 2016). 

 

Published Conference Proceedings

2011

  • Lal J. Valorization of genome-based technologies in public health. In proceedings of the 4th European Public Health Conference. European Journal of Public Health 2011, Vol. 21, Supplement 1. 10 November, Copenhagen.

  • Lal JA. Valorization of Genomics in Public Health. Biomedica Life Science Summit 2011, Eindhoven Netherlands.

2012

  • Lal JA, Schulte in den Bäumen T, Morré SA, Brand A. Valorizing Genomics in Public Health. Genetica Retraite 2011, Kerkrade Netherlands. 2012

  • Vondeling H, Lal J, Douw Karla, Cassiman JJ, Brand A. Public Health Genomics and Health Technology Assessment. In proceeds of the 9th HTAi Annual Meeting. Gac Sanit. 2012, 26(Espec Congr 2):6.

  • Brand A, Lal J. Declaration of Rome-European guidance on Public Health Genomics. In the proceedings of the 5th European Public Health Conference. European Journal of Public Health 2012, Vol.22, Supplement 2. 8 November, Malta.

2014

  • Taruscio D, Morciano C, Laricchiuta P, Mincarone P, Palazzo F, Leo CG, Sabina S, Guarino R, Auld J, Sejersen T, Sejersen K, Kemp NM, Ritchie K, Hilton-Boon M, Manson J, Kanavos P, Nicod E, Angelis A, Turdrop D, Le Cam Y, Ensini M, Senecat J, Filippini G, Minozzi S, Del Giovane C, Schünemann H, Meerpohl JJ, Stefanov R, Iskrov G, Miteva-Katrandzhieva T, Serrano-Aguilar P, Perestelo-Perez L, Trujillo-Martín MM, Pérez-Ramos J, Rivero-Santana A, Brand A, Lal JA, van Kranen HS, Bushby K, Ramet J, Siderius E, Posada M, Abaitua-Borda I, Hens- Pérez M, Alonso-Ferreira V. An overview of the RARE-Bestpractices project. In the Proceedings from the VIII international conference on rare diseases and orphan drugs (ICORD). St. Petersburg (Russia), Oct.31-Nov.2 2013. Rare Diseases and Orphan Drugs, February 2014, Volume 1 – Number 1, Supplement 1, page 14. 


Conferences

Conferences Attended (*invited presentation/lecture, **poster presentation)

  1. P3G (Public Population Project in Genomics) Conference, Luxembourg (29-30 September 2009)
  2. Dutch Network Research Pharmacogenetics (NNOF) Meeting, Utrecht University Netherlands (15 October 2009)
  3. 12th Status Seminar Chip Technologies, Sequencing & Functional Genomics, Frankfurt, Germany (February 04-05 2010)
  4. Biomedica: The Life Science Summit, Aachen, Germany (18 March 2010)
  5. Genetica Retraite, Kerkrade Netherlands (18th March 2010)
  6. Joint EuroGentest (EUGT2) and TECHGENE meeting, Leuven Belgium (09-10 February 2011)
  7. Genetica Retraite, Kerkrade Netherlands (24-25 February 2011) * 
  8. Biomedica Summit, Eindhoven Netherlands (07-08 April 2011) **
  9. Maastricht Global Health Symposium Netherlands (07 October 2011)
  10. European Public Health Conference, Copenhagen, Denmark (10-12 November 2011) *
  11. B-Team Meeting ITFoM, Vienna, Austria (08-09 December 2011)
  12. Work Package 2 Meeting ITFoM, Berlin, Germany (08 February 2012)
  13. ITFoM Consortium Meeting, Berlin, Germany (09-10 February 2012)
  14. ICT Future of Medicine Stakeholder Meeting, Berlin, Germany (13 March 2012)
  15. Genetica Retraite, Kerkrade Netherlands (15 March 2012)
  16. GRaPH-Int (Genome-based Research and Population Health International Network) Symposium, Rome, Italy (17 April 2012)
  17. European Science Foundation Stakeholder conference, Rome Italy (18 April 2012)
  18. 9th HTAi (Health Technology Assessment International) Annual Meeting, Bilbao, Spain (24-25 June 2012) *
  19. 7th meeting of the European society for Chlamydia research, VU Amsterdam, Netherlands (03 July 2012)
  20. Maastricht Global Health Symposium Netherlands (12 October 2012)
  21. Best Practices in Specialty Product Launch & Lifecycle Management Conference, Brussels, Belgium (10-11 April 2013) *
  22. European Alliance for Personalised Medicine Kick-off Meeting, Brussels, Belgium (25 February 2014)
  23. European Alliance for Personalised Medicine Meeting (EAPM), Brussels, Belgium (11 June 2014) *
  24. EAPM Conference: Integrating Personalised Medicine into EU Strategy, Brussels, Belgium (9 September 2014)
  25. EAPM Workshop I: Value of Diagnostic Information in Personalised Medicine, Brussels, Belgium (25 February 2015)
  26. EAPM Workshop II: Personalised Medicine – Towards the goal of prevention and access to treatment for all, Brussels, Belgium (25 February 2015)
  27. Workshop: Investor Readiness Training, Brightlands Campus Maastricht, The Netherlands (23 November 2015 & 18 December 2015) *
  28. International Conference on "Advancing Frontiers in Biotechnology for Sustainable Agriculture and Health", SHIATS, Allahabad India (25-26 February 2016)
  29. National Conference on ‘Intellectual Property Rights: A Significant Tool for Sustainable Agriculture”, Integral University, Lucknow, India (02 April 2016) * 

Conferences Organized (*presentation)

  1. Kick-off Meeting/ Steering Committee Meeting, Luxembourg (28-29 September 2009)
  2. PHGEN II Consortium Meeting, Como Italy (15-16 April 2010)*
  3. Second PHGEN II Consortium Meeting, Seville Spain (14-15 October 2010)
  4. Third PHGEN II Consortium Meeting, Budapest Hungary (14-15 April 2011)*
  5. Second PHGEN II Steering Committee Meeting, Luxembourg (1 July 2011)*
  6. Fourth PHGEN II Consortium Meeting, Leuven Belgium (22-23 September 2011)*
  7. Third PHGEN II Steering Comittee Meeting, Maastricht Netherlands (23 February 2012)*
  8. PHGEN II Endoresement Panel Meeting, Rome Italy (19-20 April 2012)*
  9. Workshop on the Learning-Adapting-Leveling Model, European Alliance for Personalised Medicine, Brussels Belgium (October 2013)*

Teaching Experience

Current teaching certifications:

  • Problem-based Learning Tutor (teaching) Certification from Maastricht University, the Netherlands in 2010.
    • Includes principles of problem based learning, and in teaching
    • Tasks of a planning group for a module, module construction and problem construction
    • Electronic Learning Environment, educational administration and assessment of students.
  • The Dutch BKO (University Teaching Qualification – UTQ) certificate received on 17 December 2014 at Maastricht University, the Netherlands for the following competences:
    • Professional expertise
    • Development of education
    • Delivery of education
    • Assessment and exams
    • Collaboration
    • Self-reflections

                 This certification qualifies me to teach in any university in the Netherlands.

 

Student supervision:

  • M.Sc Gobal Health thesis primary supervision
    • Student Name: Vincentas Liuima
    • Thesis title: Health policy implementation – key stakeholder mapping for a spin-off precision medicine diagnostic application
    • Duration: January 2014 to August 2014, Maastricht University, the Netherlands
  • PhD thesis involvement – Public Health Genomics
    • Student Name: Lada Leyens
    • Working Thesis title: Decision-supporting tools in Personalized Medicine.
    • Duration: January 2014 – April 2015, Maastricht University, the Netherlands
  • PhD thesis supervisor - Biotechnology 
    • Student Name: Varun Paul
    • Duration: July 2016 - till date, SHIATS India

 

Teaching activities:

 

ACADEMIC YEAR 2008-2009, DELFT UNIVERSITY OF TECHNOLOGY, NETHERLANDS

  • Lab instruction in analytical biotechnology of bachelor’s students

 

ACADEMIC YEAR 2011-2012, MAASTRICHT UNIVERSITY, NETHERLANDS

  • M.Sc European Public Health Module 7 lecture

 

ACADEMIC YEAR 2012-2013, MAASTRICHT UNIVERSITY

  • M.Sc Global Health Tutoring
  • M.Sc European Public Health Module 7 lecture

 

ACADEMIC YEAR 2013-2014, MAASTRICHT UNIVERSITY

  • M.Sc European Studies Lecture: Medical Ethics – Genetic Information and Cloning 
  • B.Sc European Public Health Practical: Workshop Negotiations – Health Strategies in Europe
  • M.Sc tutoring module New Biosciences/New Society
  • M.Sc European Public Health Module 7 lecture
  • B.Sc Health Sciences Tutoring Module
  • B.Sc European Public Health test answer sheet assessment
  • 1st year Medical Students Tutoring Module Growth and Development I
  • 1st year Medical Students Tutoring Module Regulation and Integration
  • 1st year Medical Students Tutoring Module Thinking and Doing I: Group 1
  • 1st year Medical Students Tutoring Module Thinking and Doing I: Group 2
  • 2nd year Medical Students Tutoring Module Thinking and Doing II

 

ACADEMIC YEAR 2014-2015, MAASTRICHT UNIVERSITY

  • B.Sc European Public Health 1st year Tutoring Module Infectious disease Tuberculosis
  • B.Sc European Public Health 1st Year Skills Lab Training Infectious disease Tuberculosis
  • B.Sc European Public Health 3rd year Tutoring Module Health Systems in Europe
  • 1st year Medical Students Tutoring Module Growth and Development I
  • B.Sc European Pubic Health 2nd year Tutoring Module Alcohol and Drugs Use
  • B.Sc European Public Health 1st year Tutoring Module Social and Cultural Determinants Work-related Stress and Burn-out
  • B.Sc European Public Health 1st year Skills Lab Training
  • B.Sc European Public Health 3rd year Tutoring Module Health Policies at European Level
  • M.Sc Global Health 2nd year Tutoring Module New Bioscience New Society
  • M.Sc European Public Health Lecture Public Health and Valorization A Translational Model
  • B.Sc European Public Health Tutoring Module European Institutions

 

ACADEMIC YEAR 2016-2017 (SEMESTER JULY-DECEMBER), SHIATS India

  • Basics of Molecular Genetics (B.Sc Biotechnology 3rd Semester)
  • IPR and Engineering Ethics (M.Tech Biotechnology 1st Semester)
  • IPR, Biosafety and Agricultural Biodiversity (M.Sc AG Biotechnology 1st Semester)

Additional Positions
DesignationOffice/Department
Director (I.P.C)SHIATS
DeanJacob School of Biotechnology & Bioengineering
Director (Auxiliary Units)SHIATS

Other

Memberships:

  • Life Time Member – Society for Biotechnologists, India. http://www.sbtigene.org
  • Member – P3G (Public Population Project in Genomics) Consortium. http://www.p3g.org
  • Member – HTAi (Health Technology Assessment International). www.htai.org 
  • Former Member – KIVI NIRIA (The Royal Institute of Engineers), The Netherlands. http://www.kiviniria.net
  • Alumni Member – Delft University of Technology, The Netherlands.
  • Alumni Member – LIFE, The Netherlands. http://www.svlife.nl
  • Member – Dutch Network Research Pharmacogenetics, The Netherlands.
  • Alumni Member – Sam Higginbottom Institute of Agriculture, Technology & Sciences, India.
  • Former Member – House of Representatives, AAIDU for the tenure of 2003 – 2004.
  • Former Member – ALAGIN International Club. 

Micellaneous:

  • TV appearance sporting a discussion along with colleagues regarding Public Health Genomics (15-05-2012, 11:30-14:00) on Arte TV (German channel)
  • Thirty minutes individual telephonic interview participation for a study on the harmonization strategies for HTA reimbursement and regulatory approval by Prof. Ron Goeree (McMaster University, Canada) and Mike Drummond (University of York). (06-12-2012, 15:00-15:30)
  • Received the Chancellor's award as an Alumni of Sam Higginbottom Institute of Agriculture, Technology and Sciences (SHIATS), India in December 2013 in recognition attaining the highest honor achieved for a PhD (Cum Laude) in the Netherlands.
  • Qualified the IBT (Internet Based Testing) TOEFL (Test Of English as a Foreign Language) with a score of 111, on a scale of 0 – 120 conducted by ETS (Educational Testing Service) on January 13, 2007. Qualified the CBT (Computer Based Testing) TOEFL with a score of 260 on a scale of 0 – 300, conducted by ETS on June 11, 2001.
  • Awarded Delta (Dutch Education: Learning At Top Level Abroad) Scholarship (2006-2007), for M.Sc study at Delft University Of Technology, The Netherlands. Faculty Scholarship awarded for M.Sc study, for the duration of 2005-2007, Delft University of Technology, The Netherlands. 
  • Awarded “D. N. Agarwal Award for Excellence” in the field of Science & Technology Innovation in December 2004.
  • Other awards and involvement in extra-curricular and social activities 

 

FURTHER INFORMATION:

https://in.linkedin.com/in/jonathanalal 

https://www.researchgate.net/profile/Jonathan_Lal